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Background: It is desirable to establish evidence for the selection of antipsychotics from the viewpoint of recovery
of social activity in individual patient with schizophrenia receiving medication. From this perspective, awareness of
the importance of studies about drug effectiveness on treatment discontinuation rate, remission rate, and
improvement in QOL has grown recently. In Western countries, numerous reports are available in effectiveness
studies, which are related to olanzapine and risperidone primarily, whereas evidence for other second-generation
antipsychotics (SGAs) is poor. In Japan, no effectiveness study has been reported: thus, it is desirable to collect data
that will serve as evidence for selection of the 3 SGAs approved after olanzapine.
Methods: The present study was a long-term effectiveness study under healthcare setting in Japan. It was
designed as an open-label, multicenter, randomized, comparative study involving 104-week oral treatment with 1 of
the 3 drugs (aripiprazole, blonanserin, and paliperidone) in patients with schizophrenia aged 20 years or over who
required antipsychotic medication or switching of the current medication to others for reasons such as lack of
efficacy and intolerability. The primary endpoint is treatment discontinuation rate for any causes. The secondary
endpoints include remission rate, improvement of social activity, alleviation, aggravation or recurrence of psychiatric
symptoms, and safety. The target number of subjects was set at 300.
Discussion: Because this study is expected to yield evidence regarding the selection of antipsychotics for
facilitating the recovery of social activity in patients with schizophrenia, it is considered highly valuable to perform
this effectiveness study under ordinary healthcare setting in Japan.
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Clinical studies performed during the development of
new antipsychotics (efficacy studies) often involve many
eligibility criteria for the selection of candidates and tend
to be confined to small patient groups. Furthermore, in
efficacy studies, the magnitude of changes in psychiatric
symptom score during short periods of time and adverse
reactions are evaluated independently. Because of these
features of study design, it is difficult to generalize the
results of efficacy studies readily into rationales for the
selection of antipsychotics for schizophrenia in routine
clinical practice [1]. In contrast, the goals of long-term
treatment for schizophrenia encompass improvement in
the social activity and in the Quality of Life (QOL) of pa-
tients. In this sense, effectiveness studies that can yield
new findings regarding the long-term outcome of treat-
ments have become increasingly important. In Western
countries, evidence partially supporting the selection
of antipsychotics has been accumulating from studies
that compared the long-term outcome primarily of
olanzapine and risperidone, as well as other second-
generation antipsychotics (SGAs) and first-generation
antipsychotics (FGAs) [2,3]. In Japan, however, no large-
scale effectiveness study has been carried out. Moreover,
sufficient data on the long-term outcome of treatment
with aripiprazole, blonanserin, and paliperidone, that
were marketed relatively recently, are unavailable in
Japan and in Western countries. Thus, it is desirable to
obtain evidence for the selection of these 3 drugs in
Japan.
Under such circumstances, we planned a long-term
(2-year) dosing study to evaluate the effectiveness of
aripiprazole, blonanserin, and paliperidone on discon-
tinuation rate, remission rate and improvement of social
activity in patients treated with these drugs (Japan Use-
















Figure 1 Study outline (no legend in Figure 1).Methods
Setting
This is an open-label, multicenter, randomized study in-
volving parallel-group comparison of the treatment dis-
continuation rate, remission rate, and improvement of
social activity during 2-year treatment with aripiprazole,
blonanserin, or paliperidone in patients with schizophre-
nia (Figure 1). This study complies with the Declaration
of Helsinki and Good Clinical Practice (GCP). The study
starts after having the approval for the study granted by
each institutional review board at participating clinical
site. If the participating sites have not established own
review board, the site requested the review for the study
from the review board at other medical institute and
obtained the approval (the Ethics committee of Tokyo
Women’s Medical University Hospital, the Ethics Com-
mittee of the National Center of Neurology and Psych-
iatry, the Ethics Committee of Fujita Health University
Hospital, the Ethics Committee of Tokushima Univer-
sity Hospital, Shinagawa Clinic Institutional Review
Board).
Subjects
Patients eligible for the study are outpatients with
schizophrenia aged 20 years or over who were diagnosed
according to Diagnostic and Statistical Manual of Mental
Disorders, 4th edition text revision (DSM-IV-TR), those
requiring new treatment with antipsychotics or requiring
switching of the current antipsychotics to others for rea-
sons such as lack of efficacy and intolerability. Details of
the inclusion and exclusion criteria are shown in Table 1.
Prior to participating in the study, written consent is
obtained from each patient.
The target number of subjects was set at 300, because
the major objective of this study is to explore the discon-
tinuation rate associated with SGA treatment.Blonanserin (8 24 mg/day)
Paliperidone (6 12 mg/day)




 rule (maximum of  8 weeks)
Protocol Treatment
7812
Table 1 Patient inclusion and exclusion criteria
Criteria
Patients satisfying all of the following requirements are eligible.
• Outpatients aged 20 years or over at the time of consent acquisition
• Patients with schizophrenia satisfying the DSM-IV-TR diagnostic criteria
• Patients requiring antipsychotic treatment or switching from the
current antipsychotic medication to others because of lack of efficacy,
intolerability, or other reasons
• Patients capable of issuing consent to participate in the study in writing
Exclusion criteria
Patients falling under any of the following criteria are excluded from this
study.
• Patients having a history of allergy to any component of the test
drugs or risperidone
• Patients under strong influence from drugs that suppress the central
nervous system, such as barbiturate derivatives
• Patients receiving adrenaline
• Patients receiving azole antifungal agents (excluding topical preparations)
or HIV protease inhibitors
• Patients with moderately or severely compromised renal function
(creatinine clearance less than 50 mL/min at the time of eligibility
assessment)
• Patients with poorly controlled diabetes mellitus (HbA1c (NGSP) over
8.4% at the time of eligibility assessment)
• Patients presenting with severe symptoms despite sufficient
antipsychotic treatment or patients having a history of clozapine
therapy
• Patients having other psychiatric disease in addition to schizophrenia
• Patients with complication of Parkinson’s disease
• Patients presenting with malignant syndrome or similar symptoms or
patients with water poisoning
• Patients having signs of physical exhaustion, such as dehydration and
malnutrition
• Patients having malignant tumor requiring treatment
• Patients with a history of alcohol or drug abuse
• Pregnant or possibly pregnant women, lactating women, or women
desiring to become pregnant during the study period
• Patients likely to attempt suicide (CGI-SS class 4 or higher (severe
tendency for suicide))
• Other patients judged by the physician in charge as inappropriate for
the study
DSM-IV-TR, Diagnostic and Statistical Manual of Mental Disorders, 4th edition,
text revision; HIV, human immunodeficiency virus; HbA1c, glycohemoglobin
A1c; NGSP, National Glycohemoglobin Standardization Program; CGI-SS, Clinical
Global Impression-Suicide Scale.
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Patients having issued consent to the study and eligible
for participating in the study are randomly allocated to 1
of the 3 groups treated with aripiprazole, blonanserin, or
paliperidone by the central registration center, to start
the protocol treatment (Figure 1). Each drug is adminis-
tered orally at an initial dose level or below the dose
level approved for each drug (aripiprazole, <12 mg/day;
blonanserin, <8 mg/day; and paliperidone, <6 mg/day).For subjects having received antipsychotics before the
start of the protocol treatment, the preceding antipsy-
chotics are switched to the protocol treatment during
the dose adjustment period for 4 weeks, as a rule (8
weeks at maximum). During the study period except for
the dose adjustment period, the dosage of each study
drug may be adjusted within the dosage approved
(aripiprazole, 12–30 mg/day; blonanserin, 8–24 mg/day;
and paliperidone, 6–12 mg/day), depending on the con-
dition of individual patient. Concomitant use of any an-
tipsychotics other than the study drugs is prohibited (in
case of need, concomitant use of 1 oral-dose drug is per-
mitted at dose levels within the approved range, up to 4
doses in 4 weeks). Anti-anxiety drugs or antidepressants
used concomitantly before the start of the protocol treat-
ment are continued during the study period without chan-
ging the drugs or their dosage. Adding these drugs during
the study period newly is not allowed. However, in cases
needed, it is permitted to use lorazepam concomitantly
during the study period at a frequency up to 10 doses in 4
weeks and at a daily dose level within the approved range
(3 mg/day at maximum). The study drug-treatment period
will be 104 weeks. No restriction is placed on treatment
after discontinuation of the protocol treatment. However,
it is recommended to select 1 of the 2 study drugs left
which was not used in the protocol treatment.
Table 2 lists the parameters and timing of observations
and tests. Observations and tests are conducted before
and 8, 12, 26, 52, 78, and 104 weeks after the start of the
protocol treatment (for subjects already having received
antipsychotic treatment before the start of the protocol
treatment, the tests and observations will also be
performed upon completion of the switching from the
preceding treatment to the protocol treatment). The
comprehensive capacity to give informed consent of
each patient is evaluated quantitatively using the Japa-
nese version of the MacArthur Competence Assessment
Tool for Clinical Research (MacCAT-CR) [4].
Outcome measurements
The primary endpoint of the study is the discontinuation
rate of the protocol treatment for any causes including
lack of efficacy and intolerability. Secondary endpoints are
as follows: (1) remission rate according to the definition of
Andreasen (rating below mild on all 8 items of the Positive
and Negative Syndrome Scale (PANSS) for 6 consecutive
weeks or more) [5], (2) social activity score (Personal and
Social Performance Scale (PSP), Euro QOL-5 dimension
(EQ-5D)), (3) alleviation of psychiatric symptoms in terms
of PANSS score, (4) psychiatric symptom aggravation
and recurrence rate based on PANSS, Clinical Global
Impression-Improvement (CGI-I), and Clinical Global
Impression-Suicide Scale (CGI-SS) scores (Table 3),
(5) incidence of adverse events, and (6) Drug-Induced
Table 2 Observations and tests
Eligibility assessment Protocol treatment
Week −4 to 0 0 * 8 12 26 52 78 104
Doctor’s check ○ ○ ○ ○ ○ ○ ○ ○ ○
Height†, body weight ○ ○ ○ ○ ○
Blood test‡ ○ ○ ○ ○ ○ ○
PANSS§ ○ ○ ○ ○ ○ ○ ○ ○
CGI-SS ○ ○ ○ ○ ○ ○ ○ ○
CGI-S ○ ○
CGI-I ○ ○ ○ ○ ○ ○
MacCAT-CR|| (if possible) ○
Social activity (PSP, EQ-5D) ○ ○ ○ ○ ○
DIEPSS ○ ○ ○ ○ ○ ○ ○ ○
Adverse events ○ ○ ○ ○ ○ ○ ○
PANSS, Positive and Negative Syndrome Scale; CGI-SS, Clinical Global Impression-Suicide Scale; CGI-S, Clinical Global Impression-Severity; CGI-I, Clinical Global
Impression-Improvement; MacCAT-CR, MacArthur Competence Assessment Tool for Clinical Research; PSP, Personal and Social Performance Scale; EQ-5D, Euro
Quality of life-5 dimension; DIEPSS, Drug-Induced Extrapyramidal Symptoms Scale.
In case of study discontinuation, all observations and tests except for MacCAT-CR will be performed.
* At the time of start of single-drug therapy.
† Measured only at the time of eligibility assessment.
‡ Cr (serum creatinine), HbA1c (glycohemoglobin A1c),WBC, RBC, hemoglobin, hematocrit, platelet count, AST (aspartate aminotransferase), ALT (alanine
aminotransferase), CK (creatine kinase), blood glucose, prolactin.
§ Remission is evaluated in accordance with the Andreasen definition (rating below mild on all 8 items of the PANSS for 6 consecutive months or more).
|| Assessed at the latest by Week 12.
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addition, the percentage of patients in whom multiple
antipsychotic medication is switched to monotherapy, and
the influence of the comprehensive capacity of patients on
improvement of social activity, will also be investigated.
Statistical analyses
For the primary endpoint analysis, we estimate time to
discontinuation of the protocol treatment using theTable 3 Criteria for the evaluation of psychiatric symptom
aggravation/recurrence
Satisfaction of at least 1 of the following 4 requirements
1) CGI-I is 5 (minimally worse) or higher, and at least 1 of A and B is
satisfied
A. Scored 5 (moderate severe) or higher in any of the following
PANSS items, i.e., “disturbed concept integration (P2)”, “hallucination-
based behavior (P3)”, “doubt/persecutory sense (P6)”, and “unnatural
thought content (G9)” with a score on such item(s) being higher by
2 or more points from the baseline score
B. Scored 5 (moderate severe) or higher in any of the following
PANSS items, i.e., “disturbed concept integration (P2)”, “hallucination-
based behavior (P3)”, “doubt/persecutory sense (P6)”, and “unnatural
thought content (G9)”, with a total score on these 4 items being
higher by 4 or more points from the baseline score
2) Hospitalized based on psychiatric symptom aggravation
3) CGI-SS Part 1 rating of 4 (severely suicidal) or 5 (attempted suicide),
or CGI-SS Part 2 rating of 6 (much worse) or 7 (very much worse)
4) Behaved violently, causing clinically serious self-injury, injury to other
people, or destruction of objectsKaplan-Meier method. The percentage of corresponding
cases at each point through the study period is calcu-
lated regarding the remission rate, aggravation and re-
currence rate based on psychiatric symptoms, CGI-I
score, and incidence of adverse events. The change from
the point before starting the protocol treatment to each
point is calculated regarding PANSS, social activity
evaluation (PSP, EQ-5D), CGI-SS, and DIEPSS scores.
The level of significance is set at 5% with two-tailed. The
confidence interval is estimated with 95%.
Discussion
Efficacy studies on antipsychotics can be characterized
by the enrollment of small patient groups, short dur-
ation, separate evaluation of the magnitude of change in
psychiatric symptom scores and adverse reactions. The
results of efficacy studies exhibiting these characteristics
are not always consistent with the usefulness of antipsy-
chotics experienced by physicians in clinical practice.
For this reason, there is a growing awareness of the im-
portance of the long-term assessment using effectiveness
studies: to this effect, numerous large-scale studies, such
as the Clinical Antipsychotic Trials of Intervention Ef-
fectiveness (CATIE), have been carried out in Western
countries [2,3,7-9]. In these studies, comparisons were
made among SGAs or between SGAs and FGAs, yield-
ing various findings that are useful for the selection of
drugs (primarily risperidone, olanzapine, and quetiapine)
based on long-term outcome. In the case of drugs such
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were marketed relatively recently in Japan, sufficient
long-term outcome data have not been collected, even
in Western countries.
Aripiprazole exhibits not only serotonin 5-HT2A re-
ceptor blocking activity, but also dopamine D2 and sero-
tonin 5-HT1A receptor partial agonist activity, which is
an activity that any other antipsychotics do not possess.
Aripiprazole has a low adrenaline α1 and histamine H1
receptor blocking activity and no muscarinic M1 recep-
tor blocking activity. It is less likely to exert sedative ef-
fects, to cause weight gain, or to affect the metabolic
system [10,11]. Blonanserin has dopamine D2 and sero-
tonin 5-HT2A receptor blocking activity but, unlike
other SGAs, has higher affinity for dopamine D2 recep-
tor than for serotonin 5-HT2A receptor. Therefore, it
exhibits characteristics of dopamine-serotonin antago-
nists. Much is expected of this drug regarding its effects
on acute-stage symptoms. Its affinity for adrenaline α1,
serotonin 5-HT2C, histamine H1, and muscarinic M1
receptors is low, suggesting a lower likelihood of seda-
tive action, weight gain, and influence on the metabolic
system [12]. Paliperidone is a major active metabolite of
risperidone that has D2 receptor blocking activity and a
more potent 5-HT2A receptor blocking activity and
serves as a serotonin-dopamine antagonist [13]. The
preparation of oral paliperidone adopts a drug-delivery
control system that uses osmotic pressure, enabling the
administration of treatment once a day [14]. Similar to
risperidone, paliperidone is expected to be particularly
effective against hallucination and delusion at the acute
stage of schizophrenia, however, this drug is relatively
likely to cause extrapyramidal symptoms and elevation
in blood prolactin levels [15]. Unlike the other SGAs,
paliperidone is almost not affected by the enzymes in-
volved in hepatic metabolism and is excreted primarily
(60%) in the unchanged form into the urine, allowing
the use of this drug in patients with mildly or moder-
ately compromised hepatic function [16]. Thus, the 3
study drugs differ in pharmacological profiles related to
receptor affinity and have varying metabolic and formu-
lation characteristics. In previous placebo-controlled and
active-drug-controlled short-term comparative studies
that used changes in psychiatric symptom scores as indi-
cators, these drugs exhibited an efficacy that was com-
parable to that of the other SGAs and were found to
have no noteworthy safety-profile problems compared
with the other SGAs [17-22]. Various disabilities arise
from schizophrenia that exhibit largely unmet needs.
Therefore, we may say that the collection of domestic
evidence on these 3 drugs, which are marketed in Japan,
is quite valuable.
The present work was designed as a study aimed at
collecting evidence for the selection of drugs used forthe treatment in patients with schizophrenia in clinical
practice. The inclusion criteria were set so that the study
can enroll not only patients having responded poorly to
previous antipsychotic treatment, but also patients with
poor tolerance to the antipsychotics used currently, and
patients having received no antipsychotics. The evalu-
ation of long-term outcome will use treatment discon-
tinuation rate and remission rate as indicators for the
following reasons: (1) this kind of evaluation emphasizes
effectiveness and encompasses elements such as symp-
tom control, safety, social activity improvement, and
QOL improvement, thus requiring realistic, simple and
quantitative indicators; and (2) recent naturalistic studies
revealed the necessity of ensuring adherence to the dos-
ing instructions as an indispensable factor to obtain ef-
fectiveness above a certain level, and the necessity of
estimating the extent of social activity recovery, which is
the final goal of schizophrenia treatment [23,24]. The re-
currence of schizophrenia can reduce the social activity
of patients. Therefore, it is important to determine how
to prevent its recurrence. In addition, in the present
study, the treatment discontinuation rate as a marker of
adherence was adopted as the primary endpoint. The
evaluation of this parameter is simplified by including
discontinuation of treatment for any reason. The results
of such analyses are expected to serve as the evidence
for the selection of antipsychotics to be used under di-
verse healthcare setting in Japan. The analysis using the
remission rate as an indicator of the potential for social
activity recovery in patients with schizophrenia is mean-
ingful. To evaluate the remission rate, we adopted the
Andreasen definition (rating below mild on all 8 items
of the PANSS for 6 consecutive months or more) [5].
There are no uniform criteria for judging the recurrence
of schizophrenia. However, hospitalization based on
symptom aggravation or changes in PANSS or CGI
scores is often used for the evaluation of relapse [25].
Consequently, in the present study, these indicators are
used in the evaluation of the recurrence. For the evalu-
ation of social activity improvement, assessments of
QOL using PSP and EQ-5D will also be carried out. In
contrast with the previously reported CATIE study,
which emphasized the evaluation of treatment discontinu-
ation rate [2], the present study focuses on the analysis of
the treatment discontinuation rate, accompanied by ana-
lyses of secondary measures including remission rate and
social activity, to evaluate the effectiveness of the study
drugs. Considering that this study is randomized, inter-
ventional design, we set the study period as 104 weeks, en-
abling us to evaluate remission rate and improvement in
social recovery in addition to the treatment discontinu-
ation rate. The participants enrolled in this study also in-
clude the patients who received multiple antipsychotic
medications. Switching to monotherapy is desirable from
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and alleviation of adverse reactions [26]. Thus, the present
study plans to examine the possibility of switching from
the preceding multiple antipsychotic medications to a sin-
gle antipsychotic. In addition, the comprehensive capacity
of individual patients is evaluated using the Japanese ver-
sion of the MacCAT-CR, thus allowing the assessment of
the influence of decision-making capacity on the continu-
ation of treatment and improvement in social activity.
The evaluation of effectiveness afforded by this study
is expected to yield new findings regarding the 3 study
drugs for SGA selection for patients with schizophrenia.
We planned to conduct a randomized effectiveness
study on aripiprazole, blonanserin, and paliperidone in pa-
tients with schizophrenia who had not received anti-
psychotic medication, in whom previous medication had
been suspended, or who needed a switch from the current
medication. The study period is 104 weeks. The primary
endpoint is treatment discontinuation rate. Secondary
endpoints are remission rate, improvement in social activ-
ity, adverse events. This study is expected to yield evidence
for the selection of SGAs from the viewpoint of long-term
outcome in patients with schizophrenia.
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